Eli Lilly Surges Into the $1 Trillion Club as Weight-Loss Drugs Rewire Pharma Fortunes
Eli Lilly has become the first $1 trillion pharma firm as it cashes in on booming demand for weight-loss drugs. The US fat jab company hit the milestone when its shares rose 2 percent to more than $1,060 in trading on Wall Street. The Mounjaro maker joins the elite club of firms worth trillions, such as tech giants Nvidia, Microsoft and Apple, as well as Elon Musk's Tesla and Warren Buffett's Berkshire Hathaway.
In This Article:
A Place Among Trillion-Dollar Powerhouses
The Mounjaro maker joins the elite club of firms worth trillions, such as tech giants Nvidia, Microsoft and Apple, as well as Elon Musk's Tesla and Warren Buffett's Berkshire Hathaway.
Six-Month Surge and August Setback
Eli Lilly's stock has jumped 47 percent in six months, rebounding from a setback in August when trial data on its experimental weight-loss pill orforglipron fell short of expectations.
Lilly Overtakes Novo Nordisk
The company has successfully pulled ahead of main rival Novo Nordisk, the Danish maker of Wegovy and Ozempic.
Results Drive Revenue Growth
Shares have also surged after last month's results, with revenues up 54 percent to £13.4 billion in the three months to September – in contrast with Novo Nordisk's stock, which is down by 52 percent so far this year.
Tariff Fears Fade
Investor hopes have also been bolstered as threats of tariffs on pharma imports by US President Donald Trump have receded.
Affiliate Disclosure
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
